title: Low serum concentrations of anti-Müllerian hormone are common in 53 female childhood cancer survivors.
abstract: OBJECTIVE
  Gonadal dysfunction is one of the major endocrinological late effects among childhood cancer survivors (CCSs). Periodic screening evaluation of gonadotropins and sex steroids has been recommended, although it remains difficult to predict gonadal function and reproductive capacity in childhood. We evaluated the effects of cancer treatments on the ovarian function of Japanese female CCSs by measuring serum levels of anti-Müllerian hormone (AMH) and gonadotropin.
  
  
  METHODS
  This was a retrospective, cross-sectional study at a single hospital.
  
  
  RESULTS
  Among 53 female CCSs, 28 (53%) had a decreased AMH level, while only 16 (30%) had an increased follicle-stimulating hormone (FSH) level. AMH was low in all patients with high FSH, while FSH was not elevated in 43% of patients with a low AMH level. AMH was low in 8 of 9 patients with no breast development, 11 of 14 patients with no spontaneous menstruation, and 3 of 22 patients with regular menstrual cycles.
  
  
  CONCLUSIONS
  Measurement of AMH concentration is useful as a marker of ovarian reserve in female CCSs for detecting primary gonadal deficiency, particularly among patients without increased gonadotropin levels.
authors.affiliation: Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ohta
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Namba
authors.forename: Makiko
authors.initials: M
authors.lastname: Tachibana
authors.forename: Takako
authors.initials: T
authors.lastname: Miyamura
authors.forename: Emiko
authors.initials: E
authors.lastname: Miyashita
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Hashii
authors.forename: Takaharu
authors.initials: T
authors.lastname: Oue
authors.forename: Aki
authors.initials: A
authors.lastname: Isobe
authors.forename: Tateki
authors.initials: T
authors.lastname: Tsutsui
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kimura
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ozono
mesh_terms: D000293:Adolescent; D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008598:Menstruation / Q000502:physiology; D009369:Neoplasms / Q000453:epidemiology / Q000628:therapy; D010053:Ovary / Q000503:physiopathology; D011878:Radiotherapy / Q000009:adverse effects*; D012189:Retrospective Studies; D017741:Survivors; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006062:Gonadotropins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone